Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

13 Canadian Crypto ETFs (Updated 2024)

Could the Silver Price Really Hit $100 per Ounce? (Updated 2024)

10 Top Oil-producing Countries (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

Investing in Graphene Companies (Updated 2024)

A State-by-State Guide to Cannabis in Australia (Updated 2024)

Rare Earths Stocks: 9 Biggest Companies in 2024

Can You Invest in Elon Musk’s Neuralink? (Updated 2024)

Trending Press Releases

US$30 Million Prepayment Term Sheet and Offtake Agreement Executed with a Global Commodities Trader

Radiopharm achieves Nasdaq listing of ADS

First Helium Licenses First of Two Wells Targeting Leduc Light Oil at Worsley

Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

SAGA Metals Geophysics Program Advances Drill-Ready Targets at Radar Titanium-Vanadium Project and Engages Market Maker

Mount Hope Mining: Advancing a Copper, Gold-rich Asset in the Cobar Basin of New South Wales

More Press Releases
Trending Companies

First Helium

HELI:CA

Purpose Bitcoin ETF

BTCC:CA

Soma Gold Corp.

SOMA:CA

GTI Energy

GTR:AU
More Companies
Trending Reports

2025 Crypto Outlook Report

2024 Uranium Outlook

2024 Gold Outlook Report

2024 Lithium Market Outlook

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Acumen Pharmaceuticals Inc.

NASDAQ:ABOS:US
Press Releases

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Interactive Chart

×